SCHEMBL4326533

SCHEMBL4326533

CCCCC1C(=S)NCCN1C(=O)OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.43
PRCP P42785 1/20 0.43
KMT2A Q03164 2/20 0.42
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
ELANE P08246 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
PARP1 P09874 1/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
CYP2C19 P33261 1/20 0.40
PREP P48147 1/20 0.39
TSHR P16473 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4315505 0.88 KMT2A (0.52) HTR2CPRCPKMT2APSEN1PSEN2
SCHEMBL28433612 0.85 KMT2A (0.51) HTR2CPRCPKMT2APSEN1PSEN2
SCHEMBL4389072 0.81 KMT2A (0.53) HTR2CKMT2APSEN1PSEN2APH1B
SCHEMBL12189896 0.78 KMT2A (0.55) HTR2CKMT2APSEN1PSEN2APH1B
SCHEMBL4387733 0.78 KMT2A (0.55) HTR2CKMT2APSEN1PSEN2APH1B
SCHEMBL28899278 0.78 KMT2A (0.55) HTR2CKMT2APSEN1PSEN2APH1B
SCHEMBL30841386 0.78 SMN1; SMN2 (0.53) HTR2CKMT2APSEN1PSEN2APH1B
SCHEMBL30841387 0.77 KMT2A (0.54) HTR2CKMT2APSEN1PSEN2APH1B
SCHEMBL4326538 0.76 TMEM97 (0.45) HTR2CPRCPKMT2APSEN1PSEN2
SCHEMBL4388067 0.75 KMT2A (0.52) HTR2CKMT2APSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553975-B2 Farnesyl transferase inhibitors IPSEN PHARMA S.A.S. (FR) 2009-06-30 US disclosed
US-7553975-B2 Farnesyl transferase inhibitors IPSEN PHARMA S.A.S. (FR) 2009-06-30 US disclosed
US-7553975-B2 Farnesyl transferase inhibitors IPSEN PHARMA S.A.S. (FR) 2009-06-30 US disclosed
US-7323484-B2 Farnesyl transferase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2008-01-29 US disclosed
US-7323484-B2 Farnesyl transferase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2008-01-29 US disclosed
US-7323484-B2 Farnesyl transferase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2008-01-29 US disclosed
US-20060252760-A1 Farnesyl transferase inhibitors IPSEN PHARMA S.A.S. (FR) 2006-11-09 US disclosed
US-20060079530-A1 Farnesyl transferase inhibitors IPSEN PHARMA S.A.S. (FR) 2006-04-13 US disclosed
US-7022704-B2 5,6,7, 8-tetrahydro-imidazo-(1,2a)-pyrazine derivative; useful for treating restenosis and tumor SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2006-04-04 US disclosed
EP-0904274-B1 FARNESYL TRANSFERASE INHIBITORS CONSEILS DE RECH SET D APPLIC (FR) 2005-05-25 EP disclosed
US-6673927-B2 FOR THERAPY OF TUMOR OR RESTENOSIS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2004-01-06 US disclosed
US-20030119864-A1 Farnesyl transferase inhibitors BIOMEASURE INCORPORATED, A MASSACHUSETTS CORPORATION 2003-06-26 US disclosed
US-20020013319-A1 FARNESYL TRANSFERASE INHIBITORS IPSEN PHARMA S.A.S. (FR) 2002-01-31 US disclosed
EP-0904274-A4 FARNESYL TRANSFERASE INHIBITORS BIOMEASURE INC (US) 1999-12-29 EP disclosed
EP-0904274-A1 FARNESYL TRANSFERASE INHIBITORS Biomeasure Incorporated (US) 1999-03-31 EP disclosed
WO-1997030053-A9 FARNESYL TRANSFERASE INHIBITORS 1997-10-30 WO disclosed
WO-1997030053-A1 FARNESYL TRANSFERASE INHIBITORS BIOMEASURE INCORPORATED (US) 1997-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079530-A1 Farnesyl transferase inhibitors FNTB, FNTA, LCAT HTR2C 4862/4885PRCP 736/4885KMT2A 3658/4885
US-20060252760-A1 Farnesyl transferase inhibitors FNTB, FNTA, LCAT HTR2C 4862/4885PRCP 736/4885KMT2A 3658/4885
US-20030119864-A1 Farnesyl transferase inhibitors FNTB, FNTA, LCAT HTR2C 4862/4885PRCP 736/4885KMT2A 3658/4885
US-20020013319-A1 FARNESYL TRANSFERASE INHIBITORS FNTB, FNTA, LCAT HTR2C 4862/4885PRCP 736/4885KMT2A 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.